buyWeak cluster of 12
Thronson Susan bought $25k of TRLV
director at Trulieve Cannabis Corp.. 3,968 shares at an average of $6.30, traded Nov 20, 2024, filed Nov 21, 2024.
Conviction score
33Value
$25k
3,968 shares
Holdings after
26,463
+18% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001790300-24-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | POpen-market purchase Subordinate Voting Shares | +3,968 | $6.30 | $25k | 26,463 | Nov 21, 2024 |
Related signals
Other insiders at Trulieve Cannabis Corp. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 34Weak | buy | TRLV Trulieve Cannabis Corp. | Getman Wes Chief Financial Officer | $47k | 9,500 | |
| 30Weak | buy 12 | TRLV Trulieve Cannabis Corp. | Collins Gina Chief Marketing Officer | $7,963 | 1,250 | |
| 43Moderate | buy 12 | TRLV Trulieve Cannabis Corp. | Healy Peter director | $49k | 8,130 | |
| 43Moderate | buy 12 | TRLV Trulieve Cannabis Corp. | MILLNER THOMAS L director | $49k | 8,000 | |
| 33Weak | buy 12 | TRLV Trulieve Cannabis Corp. | MORREAU JANE C director | $7,484 | 1,235 | |
| 25Weak | buy 12 | TRLV Trulieve Cannabis Corp. | May Richard S. director | $7,018 | 1,160 | |
| 32Weak | buy 12 | TRLV Trulieve Cannabis Corp. | Beshears Thad director | $50k | 7,500 | |
| 42Moderate | buy 12 | TRLV Trulieve Cannabis Corp. | Rivers Kim A. Chairman and CEO | $49k | 7,400 | |
| 44Moderate | buy 12 | TRLV Trulieve Cannabis Corp. | Jhala Nilyum Chief Technology Officer | $38k | 6,000 | |
| 38Weak | buy 12 | TRLV Trulieve Cannabis Corp. | Powers Eric Chief Legal Officer | $6,100 | 1,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.